Juno Therapeutics Inc (NASDAQ:JUNO) – FBR & Co reduced their FY2018 earnings per share estimates for Juno Therapeutics in a research note issued on Wednesday. FBR & Co analyst E. White now expects that the brokerage will post earnings per share of ($3.48) for the year, down from their prior forecast of ($3.28). FBR & Co has a “Market Perform” rating and a $30.00 price target on the stock.

Other equities analysts have also recently issued research reports about the company. Maxim Group cut their price target on Juno Therapeutics from $50.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, November 23rd. Vetr cut Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price target for the company. in a report on Monday, August 22nd. Standpoint Research assumed coverage on Juno Therapeutics in a report on Thursday, August 25th. They set a “buy” rating and a $47.00 price target for the company. Zacks Investment Research raised Juno Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 6th. Finally, SunTrust Banks Inc. lowered Juno Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $48.00 to $25.00 in a research note on Friday. Six equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $40.40.

Earnings History and Estimates for Juno Therapeutics (NASDAQ:JUNO)

TRADEMARK VIOLATION NOTICE: “FY2018 EPS Estimates for Juno Therapeutics Inc (JUNO) Decreased by FBR & Co” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of United States & international copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/29/fy2018-eps-estimates-for-juno-therapeutics-inc-juno-decreased-by-fbr-co.html.

Juno Therapeutics (NASDAQ:JUNO) traded down 4.48% during trading on Monday, hitting $21.13. The stock had a trading volume of 2,250,119 shares. The stock’s market cap is $2.17 billion. Juno Therapeutics has a 12 month low of $19.41 and a 12 month high of $57.82. The stock has a 50 day moving average price of $27.32 and a 200-day moving average price of $32.73.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.05. The firm earned $20.80 million during the quarter, compared to analysts’ expectations of $10.98 million. During the same quarter in the previous year, the business earned ($0.26) earnings per share. The business’s revenue for the quarter was up 1200.0% on a year-over-year basis.

A number of institutional investors have recently added to or reduced their stakes in the company. D.A. Davidson & CO. boosted its position in Juno Therapeutics by 40.8% in the third quarter. D.A. Davidson & CO. now owns 16,918 shares of the biopharmaceutical company’s stock worth $507,000 after buying an additional 4,900 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Juno Therapeutics by 0.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,698 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 98 shares during the last quarter. Credit Suisse AG boosted its position in Juno Therapeutics by 51.1% in the third quarter. Credit Suisse AG now owns 187,262 shares of the biopharmaceutical company’s stock worth $5,621,000 after buying an additional 63,346 shares during the last quarter. Candriam Luxembourg S.C.A. acquired a new position in Juno Therapeutics during the third quarter worth $2,401,000. Finally, Bamco Inc. NY boosted its position in Juno Therapeutics by 340.8% in the third quarter. Bamco Inc. NY now owns 443,107 shares of the biopharmaceutical company’s stock worth $13,298,000 after buying an additional 342,582 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “FY2018 EPS Estimates for Juno Therapeutics Inc (JUNO) Decreased by FBR & Co” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of United States & international copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/29/fy2018-eps-estimates-for-juno-therapeutics-inc-juno-decreased-by-fbr-co.html.

In other news, CEO Hans Edgar Bishop sold 84,035 shares of the business’s stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $30.28, for a total value of $2,544,579.80. Following the completion of the transaction, the chief executive officer now owns 2,518,537 shares of the company’s stock, valued at approximately $76,261,300.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Robert Azelby sold 12,921 shares of the business’s stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $24.14, for a total value of $311,912.94. Following the completion of the transaction, the executive vice president now directly owns 48,640 shares of the company’s stock, valued at approximately $1,174,169.60. The disclosure for this sale can be found here.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Stock Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related stocks with our FREE daily email newsletter.